5 New Mesothelioma Clinical Trials for 2022
Are There New Mesothelioma Treatments?
Nivolumab and Ipilimumab Trial
This mesothelioma clinical trial for treating patients with rare mesothelioma tumors is in phase II. This particular trial is for mesothelioma patients with rare tumors such as epithelial tumors or squamous cell carcinomas. According to this trial, immunotherapy drugs for mesothelioma with monoclonal antibodies, such as nivolumab and ipilimumab, might help a patients’s body. They claim that these antibodies assist the body’s ability to attack cancerous cells and interfere with tumor cells’ ability to grow and metastasize.
TAK-500 Clinical Trial
This phase I mesothelioma experimental trial involves 3 different treatments. The experimental groups will either undergo TAK-500 treatment alone or combined with the Pembrolizumab drug. The FDA approved the Pembrolizumab treatment, a drug to improve the outcome of patients with squamous cell mesothelioma cancer.
SO-C101 in Combination with Keytruda Clinical Trial
This phase I study evaluates the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with Perbrolizumab, or Keytruda, a mesothelioma treatment. This clinical trial is focused on adult patients with metastatic solid or advanced stage mesothelioma tumors.
Mesothelioma medical professionals are constantly advancing mesothelioma treatment through the power of clinical trials. Connect with a mesothelioma expert today to determine the next steps of your journey.